Premium
P1‐370: THE EFFICACY OF 18F‐FLUTEMETAMOL IN DISCRIMINATION OF COGNITIVE IMPAIRMENT AND DEMENTIA BY PET‐CT
Author(s) -
Bao Yiwen,
Chau Anson CM.,
Ka-Chun Chiu Patrick,
Shea Yat Fung,
Kwan Joseph SK.,
Mak Henry
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.925
Subject(s) - dementia , medicine , neuropsychology , cognitive impairment , vascular dementia , psychology , standardized uptake value , positron emission tomography , cognition , nuclear medicine , cardiology , audiology , disease , psychiatry
trial of solanezumab, an anti-amyloid antibody, in clinically normal (CN) individuals, age 65-85, with preclinical Alzheimer’s disease (AD; NCT02008357). The screening MRI data from the A4 Study provides an opportunity to determine the benchmark prevalence of ARIA-E, ARIA-H, and other MRI findings in preclinical AD. Methods: Participants who met the following eligibility requirements underwent MRI: Mini-Mental State Exam of 25-30, Logical Memory Delayed Recall score of 6-18, Clinical Dementia Rating of 0, and elevated brain amyloid on 18F-Florbetapir amyloid positron emission tomography (PET). 3-tesla MRI images including T2* gradient recalled echo and FLAIR sequences on A4 certified scanners were centrally read. Frequencies of ARIA-E, ARIA-H, and other MRI findings are reported. Results: 1268 individuals with elevated amyloid completed an A4 screening MRI. Screening MRIs showed 0 participants with ARIA-E, 212 (16.7%) with definite MH, 17 (1.3%) with definite SS, 19 (1.5%) participants had>4 definite MHs which was exclusionary for A4 participation. Other findings included 6 (0.5%) acute ischemia, 42 (3.3%) cortical infarction, 101 (8.0%) subcortical infarction. Conclusions: These analyses provide prevalence estimates of baseline ARIA and other MRI brain findings among a preclinical AD population, which may be used in planning of future preclinical AD studies.